Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat plus momelotinib for suboptimal-response myelofibrosis
ISRCTN98283910Phase 2Recruiting
- Sponsor
- United Lincolnshire Teaching Hospitals NHS Trust
- Start
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat and mivavotinib in myelofibrosis (MF), sponsored by United Lincolnshire Teaching Hospitals NHS Trust. Started Nov 2026; status: recruiting.
02
Drugs
bomedemstatmivavotinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ISRCTN98283910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN98283910.